A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer.

CONCLUSIONS: Addition of ralimetinib to GC resulted in a modest improvement in PFS.
PMID: 31791552 [PubMed - as supplied by publisher]

Source: Gynecologic Oncology - November 28, 2019 Category: Cancer & Oncology Authors: Vergote I, Heitz F, Buderath P, Powell M, Sehouli J, Lee CM, Hamilton A, Fiorica J, Moore KN, Teneriello M, Golden L, Zhang W, Pitou C, Bell R, Campbell R, Farrington DL, Bell-McGuinn K, Wenham RM Tags: Gynecol Oncol Source Type: research